Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
EMA to review Pfizer’s meningococcal vaccine
May 20, 2016Research and Development, Sales and Marketing EMA, Pfizer, meningitis, meningococcal vaccine, trumenba
Pfizer (NYSE: PFE) has announced that the European Medicines Agency has accepting the marketing authorisation application for its meningococcal group …
MSF says staff member shot dead in Central African Republic; suspends activity in the area
May 20, 2016Medical Communications Central African republic, MSF
The medical aid charity Doctors without Borders (MSF) said it is suspending activities in the Central African Republic (CAR) following an …
Nice backs Novartis’ lung cancer drug
May 20, 2016NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
May 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …
UK regulators do not back Roche’s breast cancer drug
May 20, 2016Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer, recommendation
The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …
Chugai partners with Osaka University in £62 million immunology collaboration
May 20, 2016Medical Communications, Research and Development Chugai, collaboration, immunology, osaka university
Chugai Pharmaceuticals (TOKYO: 4519) has announced a collaboration agreement with Osaka University in advanced immunology research worth up to £62 …
Celator receives FDA breakthrough therapy designation for leukaemia drug
May 20, 2016Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator
A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …
Urgent action needed on antimicrobial resistance, says government report
May 19, 2016Manufacturing and Production, Medical Communications, Research and Development ABPI, Lord Jim O'Neill, NICE, antimicrobial resistance
A new UK governmental report has warned that the global rise of antimicrobial resistance is set to worsen, with the …
Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal
May 19, 2016Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results
Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
May 19, 2016Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
Bayer makes bid for Monsanto
May 19, 2016Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover
Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
May 19, 2016Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
Roche confirms over 200 job cuts at Irish facility
May 18, 2016Manufacturing and Production Roche, clare, clarecastle, closure, irish site, job cuts, job losses
Swiss pharmaceutical company Roche (VTX: ROG) has confirmed that 240 jobs are to go at their Irish site in Clare, …
AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials
May 18, 2016Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III
AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
Breast cancer trial stopped after meeting primary endpoint early
May 18, 2016Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib
A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Boehringer Ingelheim says new studies underline efficacy of lung disease drug
May 18, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease
Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
Novartis splits pharmaceuticals division into two business units
May 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division
Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …
Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma
May 18, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo
Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
